SB Investment Advisers (UK) Ltd holds a concentrated book of 10 stocks worth $7.7B as of Q1 2026 (disclosed May 18, 2026, a ~45-day 13F lag). This quarter they trimmed Compass Inc - Class A. Their largest long position is Coupang Inc at 71% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1731509/holdings"
Use Arkolith to show SB INVESTMENT ADVISERS (UK) LTD's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No buys this quarter.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Coupang Inc CL A | $5.5B | 289.54M | 70.7% | —Held | |
| 2 | Grab Holdings Limited CLASS A ORD | $1.5B | 401.80M | 19.0% | —Held | |
| 3 | Relay Therapeutics Inc COM | $277.7M | 27.90M | 3.6% | —Held | |
| 4 | Compass Inc CL A | $160.9M | 22.00M | 2.1% | ▼−12% Reduced · −3.1M sh | |
| 5 | Vir Biotechnology Inc COM | $98.1M | 10.95M | 1.3% | ▼−17% Reduced · −2.2M sh | |
| 6 | Aurora Innovation Inc CLASS A COM | $81.6M | 19.81M | 1.1% | —Held | |
| 7 | Roivant Sciences Ltd SHS | $74.0M | 2.67M | 1.0% | ▼−84% Reduced · −13.7M sh | |
| 8 | Energy Vault Holdings Inc COM | $51.3M | 15.54M | 0.7% | ▼−16% Reduced · −3.0M sh | |
| 9 | Full Truck Alliance Co Ltd SPONSORED ADS | $43.8M | 5.27M | 0.6% | —Held | |
| 10 | Ginkgo Bioworks Holdings Inc CL A NEW | $3.7M | 610.7K | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 18, 2026 | 10 | $7.7B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 18, 2026 | 10 | $10.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 10 | $13.3B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Nov 14, 2025 | 10 | $12.6B | 13F-HR/A |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 10 | $11.0B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 10 | $11.4B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 11 | $12.1B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 12 | $10.8B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 13 | $10.1B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 13 | $11.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 14 | $12.1B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 14 | $13.1B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 14 | $12.2B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 14 | $12.0B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 13 | $13.1B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 14 | $12.6B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 15 | $21.1B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 15 | $34.3B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 16, 2021 | 11 | $32.3B | 13F-HR/A |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 16 | $51.0B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 12 | $57.8B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 8 | $24.8B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.